Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02681510
Other study ID # UW 2015-1376
Secondary ID
Status Completed
Phase Phase 4
First received February 9, 2016
Last updated September 13, 2017
Start date February 2016
Est. completion date June 13, 2016

Study information

Verified date September 2017
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will focus on enhancing future smoking cessation treatment effectiveness by piloting a potentially more powerful combination of three FDA-approved pharmacotherapies: varenicline plus combination of two types of nicotine replacement therapy (NRT) treatment (nicotine lozenge and nicotine patch). Data from this pilot study will help inform the design of future studies that would use this combination treatment as a cessation tool within the chronic care arsenal of treatments.


Description:

Recent research suggests that a new combination therapy may be especially effective in increasing long-term abstinence from smoking. A key purpose of the proposed study is to examine what types of tolerability concerns, if any, emerge from the simultaneous use of three FDA-approved cessation medications (varenicline, nicotine patch, and nicotine lozenge) and the timing of those events, in order to better assess how the use of this combination of tobacco cessation medicines can be most effectively and safely delivered and monitored. Study participants will take the three medications for 12 weeks in a manner consistent with labeling. Adverse events will be assessed at all study visits.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date June 13, 2016
Est. primary completion date June 13, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria:

- Age >17 years;

- >=5 cigarettes/day for the previous 6 months;

- alveolar CO >= 6 ppm; able to read, write and speak English;

- planning to remain in the intervention catchment area for at least 4 months; not currently taking bupropion or varenicline;

- if the participant is currently using NRT, s/he agrees to use only study medication for the duration of the study;

- free of medical contraindications to NRT and varenicline; and,

- if participant is a woman of childbearing potential, using an approved method of birth control during treatment.

Exclusion Criteria:

- Current diagnosis of/treatment for psychosis or bipolar disorder;

- suicidal ideation within the past 12 months; any history of suicide attempts; * significant hepatic or renal impairment; history of significant allergic reactions to varenicline or any type of NRT in the past;

- use of any investigational drugs in the previous 30 days. -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Varenicline
Standard FDA approved 12 weeks of treatment with Varenicline
Nicotine Transdermal Patch
Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch
Nicotine Mini
Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge

Locations

Country Name City State
United States UW CTRI Madison Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Adverse Events Assess adverse event rates in relation to participant ability to continue use of all 3 medications throughout the treatment period 12 weeks
Secondary Participant Satisfaction With Medications' Ability to Control Withdrawal Symptoms Satisfaction with Medications' Ability to Control Withdrawal Symptoms assessed on a 1-10 Likert Scale (higher value=greater satisfaction) Week 12
Secondary Participant Satisfaction With Medications' Ability to Help Participant Quit Smoking Participant Satisfaction with Medications' Ability to Help Participant Quit Smoking assessed on a 1-10 Likert Scale (higher value=greater satisfaction) Week 12
Secondary Number of Participants Who Reported Quitting at the End of Treatment Self-reported Quit Rate at End of Treatment (12 Weeks); assessed as no smoking in the 7 days prior to the Week 12 follow-up call Week 12
See also
  Status Clinical Trial Phase
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT02649556 - A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 N/A
Completed NCT03901066 - Smoking Dependence and Periodontitis
Recruiting NCT05846841 - Personalized Tobacco Treatment in Primary Care (MOTIVATE) N/A
Completed NCT03170752 - Implementing and Testing a Cardiovascular Assessment Screening Program (CASP) N/A
Completed NCT03305978 - Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan. N/A
Completed NCT00000437 - Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Phase 4
Completed NCT06105424 - BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability N/A
Active, not recruiting NCT02752022 - Monitoring the Transition From Smoking to E-cigarettes
Completed NCT03206619 - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed NCT02912000 - TEACH: Technology Evaluation to Address Child Health N/A
Completed NCT04340830 - The Effect of Smoking on Dimensional Changes of Free Gingival Graft Around Dental Implants N/A
Completed NCT02901171 - The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation N/A
Completed NCT02949648 - Electronic Cigarette Use and Quitting in Youth N/A
Completed NCT02246114 - Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women N/A
Completed NCT02945371 - Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life N/A
Completed NCT02008292 - Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors N/A
Completed NCT01898507 - Nicotine Metabolism and Low Nicotine Cigarettes N/A
Completed NCT01954407 - Young Adults' Responses to Anti-smoking Messages N/A